Cooperative Signaling Through the STAT3 and NF-kB Pathways in Subtypes of Diffuse Large B Cell Lymphoma

The activated B cell-like (ABC) subgroup of diffuse large B cell lymphoma (DLBCL) is characterized by constitutive activation of the NF- κ B pathway. Here we show that the NF-κ B pathway induces the expression of the cytokines IL-6 and IL-10 in ABC DLBCL cell lines, which also have high levels of total and phosphorylated STAT3 protein, suggesting autocrine signaling. Using RNA interference for STAT3, we defined a gene expression signature of IL-6 and IL-10 signaling through STAT3. Based on this signature, we constructed a molecular predictor of STAT3 signaling that defined a subset of ABC DLBCL tumors with high expression of STAT3, IL-6 and/or IL-10, and their downstream targets. Although the STAT3-high and STAT3-low subsets had equivalent expression of genes that distinguish ABC DLBCL from GCB DLBCL, STAT3-high ABC DLBCLs had higher expression of signatures that reflected NF-kB activity, proliferation, and glycolysis. A small-molecule inhibitor of JAK signaling, which blocked STAT3 signature expression, was toxic only for ABC DLBCL lines, and synergized with an inhibitor of NF-kB signaling. These findings suggest that the biological interplay between the STAT3 and NF-kB pathways may be exploited for the treatments of a subset of ABC DLBCLs. with 1% hydrochloric acid. The plate was read with a 96-well spectrometer using a 570-nm filter. The background was subtracted using a dual-wavelength setting of 570 and 630 nm.

[1]  L. Staudt,et al.  Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma , 2007, Leukemia.

[2]  D. Gary Gilliland,et al.  Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders , 2007, Nature Reviews Cancer.

[3]  Eric S. Lander,et al.  Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene , 2007, Cell.

[4]  G. Stark,et al.  Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. , 2007, Genes & development.

[5]  S. Cory,et al.  The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.

[6]  Zhizhuang Joe Zhao,et al.  Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth* , 2006, Journal of Biological Chemistry.

[7]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[8]  John Calvin Reed,et al.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.

[9]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[10]  V. Sasseville,et al.  Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta. , 2006, Blood.

[11]  W. Chan,et al.  Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. , 2006, Blood.

[12]  Liming Yang,et al.  A loss-of-function RNA interference screen for molecular targets in cancer , 2006, Nature.

[13]  L. Staudt,et al.  A library of gene expression signatures to illuminate normal and pathological lymphoid biology , 2006, Immunological reviews.

[14]  L. Staudt,et al.  BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Stefano Monti,et al.  Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma , 2006, The Journal of experimental medicine.

[16]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[17]  E. Hurt,et al.  The role of IL-6 and STAT3 in inflammation and cancer. , 2005, European journal of cancer.

[18]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[19]  Eric B Haura,et al.  Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer , 2005, Nature Clinical Practice Oncology.

[20]  D. Levy,et al.  Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. , 2005, Cancer research.

[21]  L. Staudt,et al.  Small Molecule Inhibitors of IKB Kinase Are Selectively Toxic for Subgroups of Diffuse Large B-Cell Lymphoma Defined by Gene Expression Profiling , 2005 .

[22]  T. Kishimoto Interleukin-6: from basic science to medicine--40 years in immunology. , 2005, Annual review of immunology.

[23]  L. Staudt,et al.  The biology of human lymphoid malignancies revealed by gene expression profiling. , 2005, Advances in immunology.

[24]  S. Korsmeyer,et al.  Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.

[25]  G. Marti,et al.  Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma , 2004, Leukemia.

[26]  P. Auron,et al.  Interleukin 1 Activates STAT3/Nuclear Factor-κB Cross-talk via a Unique TRAF6- and p65-dependent Mechanism* , 2004, Journal of Biological Chemistry.

[27]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[28]  Nicola Gebbia,et al.  STAT proteins: From normal control of cellular events to tumorigenesis , 2003, Journal of cellular physiology.

[29]  Adrian Wiestner,et al.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  K. Ohta,et al.  Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia. , 2003, Blood.

[31]  K. Rajewsky,et al.  IκB Kinase Signaling Is Essential for Maintenance of Mature B Cells , 2002, The Journal of experimental medicine.

[32]  Peter J. Murray,et al.  Shaping Gene Expression in Activated and Resting Primary Macrophages by IL-101 , 2002, The Journal of Immunology.

[33]  C. Ball,et al.  Identification of genes periodically expressed in the human cell cycle and their expression in tumors. , 2002, Molecular biology of the cell.

[34]  N. Liverton,et al.  Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. , 2002, Bioorganic & medicinal chemistry letters.

[35]  R. Gascoyne,et al.  Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. , 2002, Blood.

[36]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[37]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[38]  J. Miyazaki,et al.  Tissue-Specific Autoregulation of thestat3 Gene and Its Role in Interleukin-6-Induced Survival Signals in T Cells , 2001, Molecular and Cellular Biology.

[39]  Andreas Rosenwald,et al.  Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol , 2001, Genome Biology.

[40]  L. Staudt,et al.  Signatures of the immune response. , 2001, Immunity.

[41]  R. Coffman,et al.  Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.

[42]  Ronald W. Davis,et al.  Transcriptional regulation and function during the human cell cycle , 2001, Nature Genetics.

[43]  L. Staudt,et al.  BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. , 2000, Immunity.

[44]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[45]  J. Darnell,et al.  The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.

[46]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[47]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  D. Hilton,et al.  The SOCS proteins: a new family of negative regulators of signal transduction , 1998, Journal of leukocyte biology.

[49]  Warren S. Alexander,et al.  A family of cytokine-inducible inhibitors of signalling , 1997, Nature.

[50]  J. Blay,et al.  Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. , 1996, Cancer research.

[51]  S. Akira,et al.  Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway , 1994, Cell.

[52]  K. Anderson,et al.  Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. , 1993, Blood.

[53]  J. Banchereau,et al.  Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[54]  X. H. Wang,et al.  A possible autocrine role for interleukin-6 in two lymphoma cell lines. , 1989, Blood.

[55]  H. Asaoku,et al.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.

[56]  T. Taniguchi,et al.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.

[57]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.